髓系肉瘤的诊疗进展  

Progress of diagnosis and treatment of myeloid sarcoma

作　　者：梁晶晶 张夏林[2] 杨林花[1] Liang Jingjing;Zhang Xialin;Yang Linhua(Department of Hematology,the Second Hospital of Shanxi Medical University,Taiyuan 030001,China;Department of Hematology,the Third Hospital of Shanxi Medical University(Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital),Taiyuan 030032,China)

机构地区：[1]山西医科大学第二医院血液科,太原030001 [2]山西医科大学第三医院(山西白求恩医院山西医学科学院同济山西医院)血液科,太原030032

出　　处：《白血病．淋巴瘤》2024年第8期509-512,共4页Journal of Leukemia & Lymphoma

基　　金：山西省重点研发计划(201803D31123)。

摘　　要：髓系肉瘤(MS)是由髓系原始或未成熟细胞在髓外浸润形成的实体肿瘤。病理检查是诊断的金标准, 但误诊率高, 免疫组织化学染色可减少误诊, 分子生物学及细胞遗传学是重要的辅助诊断指标。影像学技术, 尤其是氟代脱氧葡萄糖标记的正电子发射断层扫描(FDG PET-CT)对MS诊断有重要意义。急性髓系白血病(AML)化疗方案联合造血干细胞移植是当前MS的主要治疗方法。Myeloid sarcoma(MS)is a solid tumor formed by extramedullary infiltration of primitive or immature cells of the myeloid lineage.Pathology is the gold standard for diagnosis,but the misdiagnosis rate is high.Immunohistochemical staining can reduce misdiagnosis.Molecular biology and cytogenetics are important complementary diagnostic indicators.Imaging techniques,especially fluorodeoxyglucose positron emission tomography-computed tomography(FDG PET-CT),are important for the diagnosis of MS.Acute myeloid leukemia(AML)chemotherapy regimen combined with hematopoietic stem cell transplantation is currently the main treatment for Ms.

关 键 词：髓系肉瘤 诊断 影像技术 化疗 造血干细胞移植 

分 类 号：R733[医药卫生—肿瘤]